The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to zovegalisib together with Faslodex (fulvestrant) for some sufferers with...
The U.S. Meals and Drug Administration (FDA) has granted quick monitor designation to pelareorep, an investigational immunotherapy developed by Oncolytics Biotech, to...
